June 20, 2025 07:15 PM EDT

Vertex's diabetes cell therapy allows 10 patients to come off insulin

Elizabeth Cairns

Senior biopharma journalist

Vertex Pharmaceuticals’ cell therapy for type 1 diabetes allowed 10 of 12 patients (83%) to stop taking insulin a year after they were infused, according …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Vertex's diabetes cell therapy allows 10 patients to come off insulin

Elizabeth Cairns

Senior biopharma journalist

Sign up to read this article for free.

FDA's top cell and gene therapy leaders exit agency in ongoing CBER changes

Updated: Sage's roller coaster ends in $561M acquisition by Supernus

Sage sues Biogen days after $469M buyout offer

After a quiet year, Xaira unwraps some of its AI research, eyeing a virtual cell

How a tailored ALS drug could help broaden rare disease therapies

This company has spent a decade innovating NGS-based companion diagnostics worldwide–what’s next?

Ver­tex's di­a­betes cell ther­a­py al­lows 10 pa­tients to come off in­sulin

Elizabeth Cairns

Senior biopharma journalist

Sign up to read this article for free.

FDA's top cell and gene ther­a­py lead­ers ex­it agency in on­go­ing CBER changes

Up­dat­ed: Sage's roller coast­er ends in $561M ac­qui­si­tion by Su­per­nus

Sage sues Bio­gen days af­ter $469M buy­out of­fer

Af­ter a qui­et year, Xaira un­wraps some of its AI re­search, eye­ing a vir­tu­al cell

How a tai­lored ALS drug could help broad­en rare dis­ease ther­a­pies

This com­pa­ny has spent a decade in­no­vat­ing NGS-based com­pan­ion di­ag­nos­tics world­wide–what’s next?

Vertex's diabetes cell therapy allows 10 patients to come off insulin

FDA's top cell and gene therapy leaders exit agency in ongoing CBER changes

Updated: Sage's roller coaster ends in $561M acquisition by Supernus

Sage sues Biogen days after $469M buyout offer

After a quiet year, Xaira unwraps some of its AI research, eyeing a virtual cell

How a tailored ALS drug could help broaden rare disease therapies

This company has spent a decade innovating NGS-based companion diagnostics worldwide–what’s next?